Mimetas BV participating in 325m cancer funding
Organ-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 983 entries already.
Organ-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease.
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
A 3D tumour model developed by scientists enables drug screening in metastases
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA IM Alts, has launched a Global Health Strategy following a 18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
German Bayer AG has announced it will channel at least 1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Avantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.